| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 159 | 2024 | 3552 | 15.070 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 72 | 2022 | 507 | 9.090 |
Why?
|
| Proto-Oncogene Proteins | 56 | 2021 | 2488 | 6.270 |
Why?
|
| Genes, p53 | 45 | 2023 | 1090 | 5.230 |
Why?
|
| Nuclear Proteins | 52 | 2022 | 3343 | 4.060 |
Why?
|
| Ubiquitin-Protein Ligases | 27 | 2022 | 854 | 3.350 |
Why?
|
| Mice | 168 | 2024 | 34495 | 2.730 |
Why?
|
| Li-Fraumeni Syndrome | 15 | 2023 | 158 | 2.680 |
Why?
|
| Carcinogenesis | 11 | 2023 | 1026 | 2.290 |
Why?
|
| Animals | 194 | 2024 | 59536 | 2.230 |
Why?
|
| Neoplasms, Experimental | 11 | 2018 | 750 | 2.200 |
Why?
|
| Osteosarcoma | 8 | 2023 | 929 | 2.140 |
Why?
|
| Apoptosis | 49 | 2022 | 7591 | 2.040 |
Why?
|
| Mutation | 57 | 2023 | 15179 | 1.950 |
Why?
|
| Mutation, Missense | 15 | 2023 | 1152 | 1.640 |
Why?
|
| Gene Expression Regulation, Neoplastic | 29 | 2021 | 8873 | 1.580 |
Why?
|
| Cell Transformation, Neoplastic | 21 | 2022 | 2359 | 1.540 |
Why?
|
| Disease Models, Animal | 27 | 2023 | 7222 | 1.470 |
Why?
|
| Transcriptional Activation | 17 | 2023 | 1070 | 1.390 |
Why?
|
| Tumor Suppressor Proteins | 14 | 2015 | 1823 | 1.360 |
Why?
|
| Gain of Function Mutation | 2 | 2022 | 126 | 1.360 |
Why?
|
| Mice, Transgenic | 38 | 2021 | 4143 | 1.350 |
Why?
|
| Mice, Knockout | 33 | 2023 | 5710 | 1.330 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2024 | 1215 | 1.330 |
Why?
|
| Neoplasms | 34 | 2019 | 15193 | 1.310 |
Why?
|
| Neuroendocrine Tumors | 4 | 2022 | 634 | 1.150 |
Why?
|
| Bone Neoplasms | 8 | 2023 | 2576 | 1.090 |
Why?
|
| Mice, Inbred C57BL | 41 | 2021 | 6942 | 1.070 |
Why?
|
| Transcription Factors | 20 | 2023 | 5270 | 1.060 |
Why?
|
| Fibroblasts | 13 | 2022 | 1682 | 1.050 |
Why?
|
| Gene Expression Regulation | 24 | 2020 | 4053 | 1.040 |
Why?
|
| Pancreatic Neoplasms | 7 | 2022 | 5061 | 1.020 |
Why?
|
| Organ Specificity | 5 | 2023 | 699 | 1.020 |
Why?
|
| Cell Cycle | 21 | 2015 | 2084 | 1.010 |
Why?
|
| DNA-Binding Proteins | 18 | 2020 | 4821 | 0.970 |
Why?
|
| Ribonuclease III | 3 | 2019 | 182 | 0.940 |
Why?
|
| DNA Damage | 18 | 2017 | 1954 | 0.930 |
Why?
|
| Cell Cycle Proteins | 17 | 2021 | 2045 | 0.930 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2019 | 255 | 0.890 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2018 | 221 | 0.830 |
Why?
|
| Embryonic Development | 5 | 2023 | 306 | 0.810 |
Why?
|
| Endogenous Retroviruses | 2 | 2020 | 41 | 0.790 |
Why?
|
| Carrier Proteins | 5 | 2021 | 2022 | 0.780 |
Why?
|
| Signal Transduction | 25 | 2022 | 11965 | 0.780 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 421 | 0.730 |
Why?
|
| Pancreas, Exocrine | 1 | 2020 | 22 | 0.730 |
Why?
|
| Sarcoma, Experimental | 3 | 2009 | 68 | 0.730 |
Why?
|
| Liver Neoplasms | 6 | 2023 | 4557 | 0.720 |
Why?
|
| Ultraviolet Rays | 12 | 2017 | 575 | 0.720 |
Why?
|
| Radiation, Ionizing | 3 | 2019 | 187 | 0.700 |
Why?
|
| Embryo, Mammalian | 14 | 2018 | 741 | 0.700 |
Why?
|
| Genetic Predisposition to Disease | 15 | 2021 | 5539 | 0.690 |
Why?
|
| Phenotype | 21 | 2017 | 6295 | 0.680 |
Why?
|
| Lymphoma | 5 | 2017 | 1467 | 0.680 |
Why?
|
| Aging | 7 | 2018 | 1582 | 0.670 |
Why?
|
| Cell Biology | 1 | 2018 | 16 | 0.670 |
Why?
|
| Alleles | 15 | 2023 | 2437 | 0.670 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2014 | 589 | 0.660 |
Why?
|
| Base Pair Mismatch | 1 | 2018 | 78 | 0.660 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 487 | 0.660 |
Why?
|
| Humans | 137 | 2024 | 261506 | 0.650 |
Why?
|
| E2F6 Transcription Factor | 1 | 2017 | 8 | 0.630 |
Why?
|
| Proto-Oncogene Protein c-ets-2 | 1 | 2017 | 22 | 0.630 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 470 | 0.620 |
Why?
|
| Genes, Lethal | 7 | 2006 | 120 | 0.620 |
Why?
|
| RNA, Small Nucleolar | 1 | 2017 | 25 | 0.620 |
Why?
|
| Cell Line, Tumor | 26 | 2024 | 14551 | 0.610 |
Why?
|
| Pancreatitis | 1 | 2020 | 267 | 0.610 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 674 | 0.600 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 1331 | 0.600 |
Why?
|
| Retinoids | 1 | 2018 | 164 | 0.600 |
Why?
|
| Germ-Line Mutation | 10 | 2021 | 1046 | 0.570 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 324 | 0.560 |
Why?
|
| Tamoxifen | 2 | 2018 | 876 | 0.560 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 10 | 2013 | 528 | 0.560 |
Why?
|
| Gene Editing | 1 | 2018 | 216 | 0.550 |
Why?
|
| Transcription, Genetic | 19 | 2014 | 3154 | 0.550 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 1678 | 0.550 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2013 | 1242 | 0.540 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2022 | 1216 | 0.520 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 323 | 0.520 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2018 | 1265 | 0.520 |
Why?
|
| Ubiquitin | 4 | 2014 | 344 | 0.510 |
Why?
|
| Promoter Regions, Genetic | 21 | 2014 | 3101 | 0.510 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2021 | 1724 | 0.510 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 318 | 0.510 |
Why?
|
| Homeostasis | 1 | 2020 | 950 | 0.500 |
Why?
|
| Phospholipases A2, Calcium-Independent | 1 | 2014 | 13 | 0.500 |
Why?
|
| Oxygen Consumption | 2 | 2014 | 401 | 0.500 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2008 | 803 | 0.500 |
Why?
|
| Transcriptome | 2 | 2020 | 1859 | 0.490 |
Why?
|
| Ubiquitination | 6 | 2015 | 575 | 0.490 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 589 | 0.490 |
Why?
|
| Chromosomal Instability | 2 | 2006 | 233 | 0.480 |
Why?
|
| Protein Binding | 13 | 2022 | 3438 | 0.480 |
Why?
|
| RNA, Messenger | 16 | 2010 | 6150 | 0.470 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 5112 | 0.470 |
Why?
|
| Mice, Mutant Strains | 7 | 2014 | 634 | 0.470 |
Why?
|
| Radiation Injuries | 2 | 2019 | 1411 | 0.460 |
Why?
|
| Ribosomal Proteins | 2 | 2011 | 118 | 0.460 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2023 | 2027 | 0.460 |
Why?
|
| Intestinal Mucosa | 3 | 2009 | 1081 | 0.460 |
Why?
|
| Tumor Protein p73 | 5 | 2015 | 105 | 0.450 |
Why?
|
| Gene Deletion | 8 | 2014 | 1442 | 0.450 |
Why?
|
| Reactive Oxygen Species | 4 | 2022 | 987 | 0.450 |
Why?
|
| Gene Expression | 8 | 2017 | 3570 | 0.450 |
Why?
|
| Base Sequence | 29 | 2008 | 4917 | 0.450 |
Why?
|
| Co-Repressor Proteins | 4 | 2023 | 122 | 0.450 |
Why?
|
| Genes | 8 | 2001 | 491 | 0.440 |
Why?
|
| Genes, ras | 4 | 2014 | 667 | 0.440 |
Why?
|
| Breast Neoplasms | 10 | 2022 | 15694 | 0.430 |
Why?
|
| Lymphoma, B-Cell | 3 | 2015 | 895 | 0.430 |
Why?
|
| Neoplasm Proteins | 9 | 2006 | 3230 | 0.430 |
Why?
|
| Molecular Chaperones | 4 | 2023 | 264 | 0.420 |
Why?
|
| Radiation Tolerance | 5 | 2018 | 629 | 0.410 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2017 | 5437 | 0.410 |
Why?
|
| Zebrafish Proteins | 1 | 2012 | 163 | 0.400 |
Why?
|
| X-linked Nuclear Protein | 3 | 2022 | 56 | 0.400 |
Why?
|
| Histone Chaperones | 2 | 2023 | 32 | 0.400 |
Why?
|
| Female | 63 | 2023 | 141928 | 0.400 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 234 | 0.400 |
Why?
|
| Heterozygote | 6 | 2016 | 1020 | 0.390 |
Why?
|
| Cyclins | 7 | 2002 | 456 | 0.380 |
Why?
|
| DNA | 17 | 2023 | 2693 | 0.380 |
Why?
|
| Crosses, Genetic | 7 | 2013 | 241 | 0.380 |
Why?
|
| Trans-Activators | 7 | 2015 | 1555 | 0.370 |
Why?
|
| Oncogenes | 5 | 2011 | 673 | 0.370 |
Why?
|
| Cells, Cultured | 18 | 2021 | 5637 | 0.360 |
Why?
|
| Adenocarcinoma | 3 | 2024 | 7789 | 0.360 |
Why?
|
| Inflammation | 1 | 2020 | 2522 | 0.360 |
Why?
|
| Cell Death | 3 | 2023 | 671 | 0.360 |
Why?
|
| Gene Expression Regulation, Developmental | 7 | 2011 | 1498 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2015 | 1493 | 0.350 |
Why?
|
| Limb Buds | 1 | 2009 | 34 | 0.350 |
Why?
|
| Up-Regulation | 7 | 2017 | 2450 | 0.350 |
Why?
|
| Genes, Retinoblastoma | 1 | 2009 | 86 | 0.350 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 621 | 0.350 |
Why?
|
| Protein Stability | 4 | 2020 | 370 | 0.350 |
Why?
|
| Loss of Heterozygosity | 5 | 2017 | 602 | 0.340 |
Why?
|
| Exonucleases | 2 | 2006 | 51 | 0.340 |
Why?
|
| Serine | 5 | 2004 | 388 | 0.340 |
Why?
|
| Disease Progression | 8 | 2022 | 6682 | 0.340 |
Why?
|
| Cell Proliferation | 13 | 2016 | 7226 | 0.330 |
Why?
|
| Sarcoma | 3 | 2017 | 1725 | 0.330 |
Why?
|
| Molecular Sequence Data | 23 | 2007 | 6089 | 0.330 |
Why?
|
| Cell Differentiation | 12 | 2021 | 4078 | 0.330 |
Why?
|
| Male | 52 | 2022 | 123000 | 0.320 |
Why?
|
| Introns | 8 | 2011 | 432 | 0.320 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2015 | 755 | 0.320 |
Why?
|
| Hematopoiesis | 4 | 2016 | 560 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2018 | 4549 | 0.320 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2012 | 3639 | 0.320 |
Why?
|
| Genes, p16 | 1 | 2008 | 125 | 0.320 |
Why?
|
| Limb Deformities, Congenital | 1 | 2008 | 112 | 0.310 |
Why?
|
| Genetic Engineering | 1 | 2009 | 288 | 0.310 |
Why?
|
| Myocardium | 1 | 2014 | 1313 | 0.310 |
Why?
|
| Tumor Suppressor Protein p14ARF | 4 | 2006 | 97 | 0.310 |
Why?
|
| Haploidy | 1 | 2007 | 40 | 0.310 |
Why?
|
| DNA Primers | 9 | 2013 | 1399 | 0.300 |
Why?
|
| Central Nervous System | 2 | 2009 | 436 | 0.300 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2011 | 476 | 0.300 |
Why?
|
| Rhabdomyosarcoma | 1 | 2010 | 341 | 0.300 |
Why?
|
| Cellular Senescence | 4 | 2017 | 382 | 0.290 |
Why?
|
| Repressor Proteins | 2 | 2012 | 1664 | 0.290 |
Why?
|
| Receptors, Cytokine | 2 | 2018 | 176 | 0.280 |
Why?
|
| Liver | 4 | 2014 | 2961 | 0.270 |
Why?
|
| Skin Neoplasms | 5 | 2017 | 4654 | 0.270 |
Why?
|
| Sex Factors | 6 | 2019 | 2139 | 0.270 |
Why?
|
| Alternative Splicing | 2 | 2006 | 584 | 0.270 |
Why?
|
| Collagen | 9 | 1992 | 752 | 0.270 |
Why?
|
| ras Proteins | 5 | 2019 | 770 | 0.260 |
Why?
|
| Mutant Proteins | 3 | 2011 | 234 | 0.260 |
Why?
|
| Mitochondria | 1 | 2012 | 1282 | 0.260 |
Why?
|
| Kidney | 1 | 2014 | 2146 | 0.260 |
Why?
|
| Genes, Tumor Suppressor | 7 | 2011 | 1064 | 0.260 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2007 | 244 | 0.260 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2021 | 494 | 0.250 |
Why?
|
| Cell Division | 8 | 2017 | 2489 | 0.250 |
Why?
|
| Protein Isoforms | 3 | 2013 | 842 | 0.250 |
Why?
|
| Intestine, Small | 2 | 2020 | 499 | 0.250 |
Why?
|
| Cloning, Molecular | 10 | 1998 | 1213 | 0.250 |
Why?
|
| Homozygote | 3 | 2018 | 717 | 0.250 |
Why?
|
| Retinoblastoma Protein | 2 | 2005 | 335 | 0.240 |
Why?
|
| Stem Cells | 3 | 2007 | 1213 | 0.240 |
Why?
|
| Genotype | 8 | 2016 | 4109 | 0.240 |
Why?
|
| HeLa Cells | 9 | 2013 | 1643 | 0.240 |
Why?
|
| Mice, Inbred BALB C | 6 | 2017 | 2314 | 0.240 |
Why?
|
| Down-Regulation | 6 | 2021 | 2074 | 0.240 |
Why?
|
| Recombinant Fusion Proteins | 9 | 2006 | 1555 | 0.240 |
Why?
|
| Phosphoproteins | 4 | 2013 | 1152 | 0.230 |
Why?
|
| Phosphorylation | 11 | 2019 | 4804 | 0.230 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2023 | 25 | 0.230 |
Why?
|
| Longevity | 2 | 2016 | 154 | 0.230 |
Why?
|
| Mammary Glands, Animal | 3 | 2021 | 533 | 0.230 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2010 | 882 | 0.230 |
Why?
|
| Feedback, Physiological | 2 | 2014 | 193 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 4 | 2019 | 3981 | 0.220 |
Why?
|
| Mice, Inbred Strains | 4 | 2018 | 521 | 0.220 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 2864 | 0.220 |
Why?
|
| Doxorubicin | 5 | 2014 | 3005 | 0.220 |
Why?
|
| Transfection | 11 | 2015 | 2944 | 0.220 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2017 | 421 | 0.210 |
Why?
|
| Models, Biological | 9 | 2019 | 3254 | 0.210 |
Why?
|
| Blotting, Western | 6 | 2012 | 3536 | 0.210 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2017 | 489 | 0.210 |
Why?
|
| Skin | 3 | 2017 | 1259 | 0.210 |
Why?
|
| Protein Structure, Tertiary | 4 | 2007 | 1487 | 0.210 |
Why?
|
| Models, Animal | 3 | 2014 | 664 | 0.200 |
Why?
|
| Blotting, Northern | 8 | 2003 | 682 | 0.200 |
Why?
|
| Polyamines | 1 | 2021 | 75 | 0.200 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 10331 | 0.200 |
Why?
|
| Wnt Signaling Pathway | 2 | 2021 | 430 | 0.200 |
Why?
|
| Transgenes | 2 | 2017 | 557 | 0.200 |
Why?
|
| Hepatocytes | 2 | 2022 | 351 | 0.200 |
Why?
|
| Islets of Langerhans | 1 | 2022 | 229 | 0.200 |
Why?
|
| Gamma Rays | 3 | 2004 | 242 | 0.200 |
Why?
|
| Pseudogenes | 1 | 2001 | 81 | 0.200 |
Why?
|
| S Phase | 2 | 1999 | 281 | 0.190 |
Why?
|
| Primary Cell Culture | 2 | 2021 | 208 | 0.190 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2013 | 503 | 0.190 |
Why?
|
| Polymerization | 1 | 2020 | 17 | 0.190 |
Why?
|
| Models, Theoretical | 2 | 2008 | 785 | 0.190 |
Why?
|
| Amino Acid Sequence | 14 | 2007 | 4233 | 0.190 |
Why?
|
| Duodenal Neoplasms | 1 | 2021 | 138 | 0.190 |
Why?
|
| Immunohistochemistry | 6 | 2016 | 7548 | 0.190 |
Why?
|
| Penetrance | 1 | 2021 | 126 | 0.190 |
Why?
|
| Osteoblasts | 3 | 2021 | 370 | 0.190 |
Why?
|
| DNA Repair | 3 | 2010 | 1872 | 0.190 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2021 | 141 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 2 | 2019 | 848 | 0.190 |
Why?
|
| Chromatin Immunoprecipitation | 2 | 2020 | 518 | 0.190 |
Why?
|
| beta Catenin | 2 | 2021 | 688 | 0.180 |
Why?
|
| Carcinosarcoma | 1 | 2021 | 146 | 0.180 |
Why?
|
| Ribonucleotide Reductases | 1 | 2000 | 51 | 0.180 |
Why?
|
| Cell Plasticity | 1 | 2020 | 66 | 0.180 |
Why?
|
| Sequence Deletion | 5 | 2016 | 875 | 0.180 |
Why?
|
| DNA Mutational Analysis | 9 | 2017 | 2283 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2020 | 166 | 0.180 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 1999 | 26 | 0.170 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2019 | 82 | 0.170 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2004 | 611 | 0.170 |
Why?
|
| Point Mutation | 3 | 2014 | 769 | 0.170 |
Why?
|
| Genes, myc | 2 | 2011 | 358 | 0.170 |
Why?
|
| Heart | 1 | 2006 | 1223 | 0.170 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 1443 | 0.170 |
Why?
|
| 3T3 Cells | 7 | 2011 | 355 | 0.170 |
Why?
|
| Lung Neoplasms | 8 | 2017 | 11538 | 0.170 |
Why?
|
| Protein Domains | 1 | 2020 | 314 | 0.170 |
Why?
|
| Rats | 8 | 2018 | 6086 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 2054 | 0.170 |
Why?
|
| Histones | 5 | 2018 | 1466 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 3 | 2013 | 1130 | 0.170 |
Why?
|
| Peptide Hydrolases | 2 | 2011 | 256 | 0.170 |
Why?
|
| Gene Knock-In Techniques | 5 | 2021 | 171 | 0.170 |
Why?
|
| Antineoplastic Agents | 5 | 2019 | 14289 | 0.170 |
Why?
|
| Mutation Rate | 1 | 2019 | 223 | 0.170 |
Why?
|
| Germ Cells | 1 | 2021 | 335 | 0.170 |
Why?
|
| Hyperpigmentation | 2 | 2016 | 32 | 0.170 |
Why?
|
| Chromosomes, Human, X | 1 | 2019 | 192 | 0.160 |
Why?
|
| Fungal Proteins | 3 | 1998 | 254 | 0.160 |
Why?
|
| Spondylarthropathies | 1 | 2018 | 4 | 0.160 |
Why?
|
| Recombinational DNA Repair | 1 | 2018 | 79 | 0.160 |
Why?
|
| Protein Transport | 1 | 2020 | 734 | 0.160 |
Why?
|
| Chromosome Mapping | 5 | 2006 | 1471 | 0.160 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2018 | 31 | 0.160 |
Why?
|
| DNA End-Joining Repair | 1 | 2018 | 86 | 0.160 |
Why?
|
| Keratinocytes | 2 | 2017 | 241 | 0.160 |
Why?
|
| Phosphoserine | 2 | 2001 | 107 | 0.160 |
Why?
|
| Cell Survival | 8 | 2015 | 3045 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2018 | 1538 | 0.160 |
Why?
|
| Biomarkers | 3 | 2020 | 5047 | 0.150 |
Why?
|
| fas Receptor | 2 | 2002 | 185 | 0.150 |
Why?
|
| Cell Line | 9 | 2013 | 5114 | 0.150 |
Why?
|
| Leupeptins | 2 | 2014 | 68 | 0.150 |
Why?
|
| Thymus Gland | 2 | 2004 | 294 | 0.150 |
Why?
|
| Melanocytes | 2 | 2016 | 219 | 0.150 |
Why?
|
| Laryngeal Neoplasms | 1 | 2001 | 518 | 0.150 |
Why?
|
| RNA Splicing | 2 | 2017 | 370 | 0.150 |
Why?
|
| Obesity | 2 | 2023 | 2884 | 0.150 |
Why?
|
| Receptors, Endothelin | 2 | 2014 | 24 | 0.150 |
Why?
|
| Receptors, Angiotensin | 2 | 2014 | 44 | 0.150 |
Why?
|
| Receptors, Interleukin | 4 | 2018 | 97 | 0.150 |
Why?
|
| Mice, Nude | 5 | 2021 | 4307 | 0.150 |
Why?
|
| Transformation, Genetic | 3 | 2001 | 57 | 0.140 |
Why?
|
| Pancreas | 1 | 2020 | 718 | 0.140 |
Why?
|
| NF-kappa B | 2 | 2013 | 1549 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 677 | 0.140 |
Why?
|
| RNA, Neoplasm | 2 | 2014 | 771 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2018 | 441 | 0.140 |
Why?
|
| Bromodeoxyuridine | 3 | 2009 | 139 | 0.140 |
Why?
|
| Mitosis | 4 | 2007 | 615 | 0.140 |
Why?
|
| Genetic Vectors | 3 | 2003 | 1694 | 0.140 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 253 | 0.140 |
Why?
|
| Interleukin-27 | 1 | 2016 | 8 | 0.140 |
Why?
|
| Oncogene Proteins | 2 | 2005 | 354 | 0.140 |
Why?
|
| Receptor, Endothelin A | 1 | 2016 | 18 | 0.140 |
Why?
|
| Interleukin-17 | 1 | 2018 | 250 | 0.140 |
Why?
|
| Carcinogens | 1 | 2017 | 384 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2018 | 574 | 0.140 |
Why?
|
| Cell Growth Processes | 2 | 2014 | 342 | 0.140 |
Why?
|
| Contact Inhibition | 1 | 1995 | 8 | 0.140 |
Why?
|
| Mouth Neoplasms | 1 | 2001 | 713 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2022 | 1546 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2020 | 2291 | 0.130 |
Why?
|
| Clonal Evolution | 1 | 2017 | 253 | 0.130 |
Why?
|
| NFI Transcription Factors | 1 | 2015 | 74 | 0.130 |
Why?
|
| Animals, Genetically Modified | 2 | 2015 | 406 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2013 | 327 | 0.130 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2015 | 160 | 0.130 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2007 | 997 | 0.130 |
Why?
|
| Mitochondrial Turnover | 1 | 2014 | 6 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 8 | 2014 | 3203 | 0.120 |
Why?
|
| Drug Synergism | 1 | 2018 | 1313 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2016 | 242 | 0.120 |
Why?
|
| Cycloheximide | 1 | 2014 | 97 | 0.120 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2006 | 430 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 15 | 2003 | 5395 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2006 | 1697 | 0.120 |
Why?
|
| Dactinomycin | 1 | 2014 | 145 | 0.120 |
Why?
|
| Pedigree | 7 | 2011 | 1890 | 0.120 |
Why?
|
| Response Elements | 1 | 2014 | 193 | 0.120 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2014 | 73 | 0.120 |
Why?
|
| B-Lymphocytes | 2 | 2010 | 1294 | 0.120 |
Why?
|
| NFATC Transcription Factors | 1 | 2014 | 96 | 0.120 |
Why?
|
| Ploidies | 2 | 2004 | 248 | 0.120 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2014 | 164 | 0.120 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2015 | 203 | 0.120 |
Why?
|
| Cerebellum | 2 | 2007 | 449 | 0.120 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2014 | 196 | 0.120 |
Why?
|
| Injections | 1 | 2014 | 285 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 5178 | 0.110 |
Why?
|
| Chromosome Inversion | 1 | 2014 | 182 | 0.110 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2015 | 287 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2017 | 2508 | 0.110 |
Why?
|
| Psoriasis | 1 | 2014 | 126 | 0.110 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2013 | 430 | 0.110 |
Why?
|
| Binding Sites | 6 | 2012 | 2171 | 0.110 |
Why?
|
| Chickens | 4 | 2010 | 523 | 0.110 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2013 | 45 | 0.110 |
Why?
|
| Animals, Newborn | 3 | 2007 | 1338 | 0.110 |
Why?
|
| Translocation, Genetic | 2 | 2015 | 1245 | 0.110 |
Why?
|
| Transcription Factor RelA | 1 | 2013 | 184 | 0.110 |
Why?
|
| Gene Expression Profiling | 5 | 2017 | 5159 | 0.110 |
Why?
|
| Th1 Cells | 1 | 2014 | 250 | 0.110 |
Why?
|
| Fatty Liver | 1 | 2014 | 235 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 2 | 1995 | 467 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 2 | 2007 | 3976 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 840 | 0.110 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 1993 | 445 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 278 | 0.110 |
Why?
|
| beta-Galactosidase | 2 | 2009 | 211 | 0.110 |
Why?
|
| Epithelial Cells | 3 | 2008 | 1818 | 0.110 |
Why?
|
| Prostatic Neoplasms | 4 | 2022 | 5767 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2015 | 519 | 0.100 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2011 | 26 | 0.100 |
Why?
|
| Proteolysis | 1 | 2014 | 370 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 6207 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2010 | 9180 | 0.100 |
Why?
|
| Genomics | 3 | 2017 | 2738 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2022 | 1797 | 0.100 |
Why?
|
| Research Report | 1 | 2012 | 144 | 0.100 |
Why?
|
| Blotting, Southern | 2 | 2011 | 406 | 0.100 |
Why?
|
| Smad Proteins | 1 | 2011 | 88 | 0.100 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2012 | 194 | 0.100 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2011 | 73 | 0.100 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 242 | 0.100 |
Why?
|
| Glioma | 1 | 2022 | 1963 | 0.100 |
Why?
|
| DNA-Activated Protein Kinase | 2 | 2022 | 76 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 973 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 566 | 0.100 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1991 | 220 | 0.100 |
Why?
|
| Myocytes, Cardiac | 2 | 2007 | 764 | 0.100 |
Why?
|
| Exons | 5 | 2003 | 1328 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2007 | 703 | 0.100 |
Why?
|
| Flow Cytometry | 3 | 2018 | 3033 | 0.100 |
Why?
|
| Zinc Fingers | 2 | 2005 | 205 | 0.090 |
Why?
|
| Cerebellar Ataxia | 1 | 2011 | 72 | 0.090 |
Why?
|
| Casein Kinase II | 3 | 2001 | 69 | 0.090 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 1999 | 176 | 0.090 |
Why?
|
| ErbB Receptors | 3 | 2022 | 2295 | 0.090 |
Why?
|
| Lipids | 1 | 2014 | 644 | 0.090 |
Why?
|
| Oligonucleotides | 2 | 2010 | 227 | 0.090 |
Why?
|
| Immunoprecipitation | 2 | 2013 | 591 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2014 | 492 | 0.090 |
Why?
|
| Retina | 1 | 2014 | 532 | 0.090 |
Why?
|
| Cell Movement | 4 | 2016 | 2466 | 0.090 |
Why?
|
| 5' Untranslated Regions | 1 | 2010 | 93 | 0.090 |
Why?
|
| Feedback | 2 | 2010 | 198 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2003 | 367 | 0.090 |
Why?
|
| Genes, Dominant | 3 | 2011 | 331 | 0.090 |
Why?
|
| Survival Rate | 4 | 2007 | 12221 | 0.090 |
Why?
|
| Protein Multimerization | 1 | 2011 | 240 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 1121 | 0.090 |
Why?
|
| Proto-Oncogenes | 1 | 1990 | 202 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 132 | 0.090 |
Why?
|
| Osteogenesis | 3 | 2021 | 271 | 0.090 |
Why?
|
| E2F3 Transcription Factor | 1 | 2009 | 23 | 0.090 |
Why?
|
| Nevus | 1 | 2010 | 107 | 0.090 |
Why?
|
| Adipocytes | 1 | 2012 | 305 | 0.090 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2011 | 132 | 0.090 |
Why?
|
| Precipitin Tests | 3 | 2003 | 329 | 0.090 |
Why?
|
| Chromosome Aberrations | 1 | 2017 | 1960 | 0.090 |
Why?
|
| Retinoblastoma | 1 | 2011 | 200 | 0.090 |
Why?
|
| Macrophages | 1 | 2016 | 1304 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 479 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2010 | 343 | 0.090 |
Why?
|
| RNA, Small Interfering | 4 | 2022 | 2216 | 0.090 |
Why?
|
| Cisplatin | 3 | 2016 | 2432 | 0.090 |
Why?
|
| DNA Replication | 2 | 2004 | 744 | 0.090 |
Why?
|
| CD3 Complex | 1 | 2010 | 314 | 0.090 |
Why?
|
| Tumor Burden | 2 | 2012 | 1987 | 0.080 |
Why?
|
| Cell Nucleus | 5 | 2004 | 1620 | 0.080 |
Why?
|
| Genome, Human | 2 | 2015 | 1869 | 0.080 |
Why?
|
| Bone Marrow | 2 | 2007 | 2358 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2022 | 986 | 0.080 |
Why?
|
| Exoribonucleases | 2 | 2006 | 42 | 0.080 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 1 | 2008 | 45 | 0.080 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2008 | 98 | 0.080 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 395 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2014 | 731 | 0.080 |
Why?
|
| Mice, 129 Strain | 2 | 2021 | 170 | 0.080 |
Why?
|
| Enzyme Activation | 4 | 2007 | 1764 | 0.080 |
Why?
|
| Restriction Mapping | 4 | 1998 | 264 | 0.080 |
Why?
|
| Hippocampus | 1 | 2014 | 915 | 0.080 |
Why?
|
| Breast | 3 | 2021 | 1344 | 0.080 |
Why?
|
| 14-3-3 Proteins | 2 | 2006 | 143 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2010 | 403 | 0.080 |
Why?
|
| Pregnancy | 4 | 2023 | 7573 | 0.080 |
Why?
|
| Methylation | 3 | 2015 | 597 | 0.080 |
Why?
|
| Immunoblotting | 4 | 2013 | 886 | 0.080 |
Why?
|
| Time Factors | 8 | 2017 | 12926 | 0.080 |
Why?
|
| G1 Phase | 2 | 2000 | 285 | 0.080 |
Why?
|
| Models, Genetic | 2 | 2014 | 1113 | 0.080 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 93 | 0.080 |
Why?
|
| Actins | 1 | 2010 | 608 | 0.080 |
Why?
|
| Growth | 1 | 2007 | 117 | 0.080 |
Why?
|
| Tripartite Motif Proteins | 3 | 2014 | 55 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 10001 | 0.070 |
Why?
|
| Protein Biosynthesis | 2 | 2010 | 889 | 0.070 |
Why?
|
| Polymorphism, Genetic | 3 | 2014 | 1450 | 0.070 |
Why?
|
| Papilloma | 4 | 2007 | 74 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2006 | 74 | 0.070 |
Why?
|
| X-Ray Microtomography | 2 | 2018 | 141 | 0.070 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2006 | 40 | 0.070 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2006 | 32 | 0.070 |
Why?
|
| Caffeine | 1 | 2006 | 87 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2008 | 397 | 0.070 |
Why?
|
| DNA Modification Methylases | 1 | 2006 | 172 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2014 | 5319 | 0.070 |
Why?
|
| Centromere | 2 | 2023 | 97 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 673 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 2265 | 0.070 |
Why?
|
| Spermatogenesis | 1 | 2007 | 308 | 0.070 |
Why?
|
| Medical Informatics | 1 | 2008 | 198 | 0.070 |
Why?
|
| Erythrocytes | 1 | 2006 | 339 | 0.070 |
Why?
|
| Adipogenesis | 2 | 2021 | 105 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 2527 | 0.070 |
Why?
|
| Hepatomegaly | 1 | 2005 | 69 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2009 | 874 | 0.070 |
Why?
|
| DNA Repair Enzymes | 1 | 2006 | 237 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2012 | 806 | 0.060 |
Why?
|
| RNA Interference | 3 | 2015 | 1408 | 0.060 |
Why?
|
| Mosaicism | 1 | 2007 | 272 | 0.060 |
Why?
|
| Histone Acetyltransferases | 1 | 2007 | 411 | 0.060 |
Why?
|
| Simian virus 40 | 4 | 1991 | 137 | 0.060 |
Why?
|
| Temperature | 2 | 2000 | 506 | 0.060 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 1995 | 118 | 0.060 |
Why?
|
| Endopeptidases | 1 | 2006 | 220 | 0.060 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2006 | 216 | 0.060 |
Why?
|
| Ankyrins | 1 | 2005 | 104 | 0.060 |
Why?
|
| Teratoma | 2 | 1999 | 236 | 0.060 |
Why?
|
| Gene Silencing | 1 | 2007 | 837 | 0.060 |
Why?
|
| Lod Score | 1 | 2004 | 157 | 0.060 |
Why?
|
| Drosophila | 2 | 2007 | 839 | 0.060 |
Why?
|
| HCT116 Cells | 2 | 2015 | 348 | 0.060 |
Why?
|
| Fetal Death | 1 | 2004 | 113 | 0.060 |
Why?
|
| Mathematics | 1 | 2004 | 136 | 0.060 |
Why?
|
| Genetic Markers | 2 | 2004 | 974 | 0.060 |
Why?
|
| High Mobility Group Proteins | 2 | 2001 | 59 | 0.060 |
Why?
|
| Haplotypes | 2 | 2014 | 856 | 0.060 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2004 | 163 | 0.060 |
Why?
|
| E2F1 Transcription Factor | 2 | 2009 | 206 | 0.060 |
Why?
|
| Multigene Family | 1 | 2005 | 425 | 0.060 |
Why?
|
| cdc25 Phosphatases | 1 | 2004 | 97 | 0.060 |
Why?
|
| Proteins | 3 | 2000 | 1963 | 0.060 |
Why?
|
| Nucleotides | 2 | 2004 | 164 | 0.060 |
Why?
|
| Genes, Recessive | 1 | 2004 | 200 | 0.060 |
Why?
|
| Telomere | 1 | 2007 | 505 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2010 | 1146 | 0.060 |
Why?
|
| Middle Aged | 9 | 2021 | 86204 | 0.060 |
Why?
|
| Amino Acid Substitution | 3 | 2018 | 644 | 0.060 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 4638 | 0.060 |
Why?
|
| Choroid Plexus | 3 | 1988 | 31 | 0.060 |
Why?
|
| Neural Tube Defects | 1 | 2007 | 341 | 0.060 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1994 | 261 | 0.060 |
Why?
|
| Ligases | 1 | 2003 | 70 | 0.060 |
Why?
|
| Lactation | 2 | 2002 | 210 | 0.060 |
Why?
|
| Teratocarcinoma | 2 | 1999 | 24 | 0.060 |
Why?
|
| Whole-Body Irradiation | 2 | 2009 | 307 | 0.060 |
Why?
|
| MCF-7 Cells | 2 | 2015 | 550 | 0.060 |
Why?
|
| alpha-Thalassemia | 1 | 2022 | 11 | 0.060 |
Why?
|
| Ubiquitins | 1 | 2003 | 86 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 2 | 1998 | 205 | 0.050 |
Why?
|
| Methoxsalen | 1 | 2002 | 6 | 0.050 |
Why?
|
| Pleural Neoplasms | 1 | 2007 | 470 | 0.050 |
Why?
|
| Cerebral Ventricle Neoplasms | 3 | 1988 | 81 | 0.050 |
Why?
|
| Adult | 13 | 2021 | 77950 | 0.050 |
Why?
|
| Neuroblastoma | 2 | 2005 | 686 | 0.050 |
Why?
|
| Aged | 7 | 2021 | 70117 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2001 | 844 | 0.050 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2001 | 354 | 0.050 |
Why?
|
| Giant Cells | 1 | 2002 | 69 | 0.050 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 482 | 0.050 |
Why?
|
| HEK293 Cells | 2 | 2018 | 1489 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2007 | 544 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2017 | 9244 | 0.050 |
Why?
|
| Muridae | 1 | 2001 | 21 | 0.050 |
Why?
|
| Smad3 Protein | 2 | 2013 | 129 | 0.050 |
Why?
|
| Epidermis | 1 | 2002 | 188 | 0.050 |
Why?
|
| Mental Retardation, X-Linked | 1 | 2022 | 94 | 0.050 |
Why?
|
| Genetic Linkage | 2 | 2005 | 512 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2012 | 726 | 0.050 |
Why?
|
| Son of Sevenless Proteins | 1 | 2001 | 7 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 6915 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2022 | 1439 | 0.050 |
Why?
|
| Chondrogenesis | 1 | 2021 | 67 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2021 | 6100 | 0.050 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2001 | 44 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2001 | 448 | 0.050 |
Why?
|
| COP9 Signalosome Complex | 2 | 2011 | 72 | 0.050 |
Why?
|
| Haploinsufficiency | 2 | 2013 | 294 | 0.050 |
Why?
|
| Acetamides | 1 | 2001 | 113 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2003 | 226 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 165 | 0.050 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 1910 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2005 | 591 | 0.050 |
Why?
|
| Genes, Synthetic | 1 | 2000 | 26 | 0.050 |
Why?
|
| Integrases | 1 | 2002 | 262 | 0.050 |
Why?
|
| Genomic Library | 2 | 1998 | 41 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2003 | 613 | 0.050 |
Why?
|
| Terminal Repeat Sequences | 1 | 1999 | 27 | 0.050 |
Why?
|
| Spermatocytes | 1 | 1999 | 43 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 1866 | 0.050 |
Why?
|
| Gene Library | 1 | 2001 | 294 | 0.050 |
Why?
|
| Imidazoles | 2 | 2010 | 999 | 0.040 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 1879 | 0.040 |
Why?
|
| Risk Factors | 3 | 2014 | 17523 | 0.040 |
Why?
|
| Pyridazines | 1 | 2022 | 293 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2022 | 434 | 0.040 |
Why?
|
| Cell Lineage | 2 | 2015 | 668 | 0.040 |
Why?
|
| Genes, X-Linked | 1 | 2019 | 66 | 0.040 |
Why?
|
| Growth Disorders | 2 | 2011 | 218 | 0.040 |
Why?
|
| Codon | 3 | 2010 | 241 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 338 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 1999 | 875 | 0.040 |
Why?
|
| Cartilage | 3 | 1991 | 128 | 0.040 |
Why?
|
| Transcription Factors, TFII | 1 | 1999 | 24 | 0.040 |
Why?
|
| Transcription Factor TFIID | 1 | 1999 | 26 | 0.040 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 1999 | 54 | 0.040 |
Why?
|
| Transcription Factor DP1 | 1 | 1999 | 57 | 0.040 |
Why?
|
| United States | 4 | 2021 | 15433 | 0.040 |
Why?
|
| Cyclin A | 1 | 1999 | 47 | 0.040 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2010 | 108 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2002 | 435 | 0.040 |
Why?
|
| E2F Transcription Factors | 1 | 1999 | 132 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2001 | 652 | 0.040 |
Why?
|
| Prognosis | 5 | 2021 | 21713 | 0.040 |
Why?
|
| Protein Interaction Maps | 1 | 2019 | 149 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 206 | 0.040 |
Why?
|
| Plasmids | 4 | 2001 | 837 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1999 | 143 | 0.040 |
Why?
|
| Neurons | 2 | 2007 | 2287 | 0.040 |
Why?
|
| Thyroid Gland | 2 | 2011 | 355 | 0.040 |
Why?
|
| Aspergillus nidulans | 1 | 1998 | 28 | 0.040 |
Why?
|
| Testicular Neoplasms | 2 | 1999 | 529 | 0.040 |
Why?
|
| Octamer Transcription Factors | 1 | 2018 | 19 | 0.040 |
Why?
|
| Genes, Fungal | 1 | 1998 | 84 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2001 | 731 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2021 | 419 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2001 | 621 | 0.040 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 1997 | 23 | 0.040 |
Why?
|
| Retinal Dehydrogenase | 1 | 2018 | 91 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2018 | 103 | 0.040 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2018 | 129 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1999 | 259 | 0.040 |
Why?
|
| Blastomeres | 1 | 1997 | 24 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 3578 | 0.040 |
Why?
|
| Quinazolines | 1 | 2022 | 923 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 1998 | 334 | 0.040 |
Why?
|
| Autoantigens | 1 | 1998 | 234 | 0.040 |
Why?
|
| Pancreatitis, Chronic | 1 | 2018 | 116 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 1073 | 0.040 |
Why?
|
| Sp1 Transcription Factor | 2 | 2010 | 188 | 0.040 |
Why?
|
| Promyelocytic Leukemia Protein | 2 | 2013 | 55 | 0.040 |
Why?
|
| Prostate | 1 | 2022 | 1088 | 0.040 |
Why?
|
| Cyclin E | 1 | 1999 | 267 | 0.040 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1997 | 95 | 0.040 |
Why?
|
| Creatine Kinase | 2 | 1995 | 92 | 0.040 |
Why?
|
| Caenorhabditis elegans | 1 | 2018 | 268 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1999 | 639 | 0.040 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1996 | 18 | 0.040 |
Why?
|
| Cosmids | 1 | 1996 | 40 | 0.040 |
Why?
|
| Luciferases | 2 | 2010 | 445 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 1998 | 362 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1000 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2001 | 2483 | 0.030 |
Why?
|
| Indoles | 1 | 2001 | 1009 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2015 | 104 | 0.030 |
Why?
|
| Gene Order | 1 | 2015 | 111 | 0.030 |
Why?
|
| Aflatoxin B1 | 1 | 1995 | 7 | 0.030 |
Why?
|
| Antigens, Polyomavirus Transforming | 2 | 1993 | 110 | 0.030 |
Why?
|
| Gene Frequency | 3 | 2004 | 1163 | 0.030 |
Why?
|
| Jejunum | 1 | 1997 | 216 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2015 | 89 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 14889 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2015 | 114 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 1994 | 931 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 1997 | 423 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 826 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 1998 | 260 | 0.030 |
Why?
|
| Suppression, Genetic | 2 | 1994 | 67 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 1996 | 309 | 0.030 |
Why?
|
| Acids | 1 | 1994 | 38 | 0.030 |
Why?
|
| Ganglia, Spinal | 1 | 1996 | 237 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2015 | 290 | 0.030 |
Why?
|
| RNA | 2 | 2005 | 1013 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2015 | 317 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1997 | 641 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 1995 | 237 | 0.030 |
Why?
|
| Cell Count | 1 | 1995 | 508 | 0.030 |
Why?
|
| Listeriosis | 1 | 2014 | 35 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2014 | 73 | 0.030 |
Why?
|
| Muscle, Skeletal | 2 | 2014 | 1270 | 0.030 |
Why?
|
| Listeria monocytogenes | 1 | 2014 | 52 | 0.030 |
Why?
|
| Exome | 1 | 2019 | 1239 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2004 | 1589 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 1037 | 0.030 |
Why?
|
| Smoking | 1 | 2003 | 2440 | 0.030 |
Why?
|
| Protein Denaturation | 1 | 2013 | 70 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2018 | 541 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1995 | 396 | 0.030 |
Why?
|
| Proteomics | 1 | 2021 | 1380 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 733 | 0.030 |
Why?
|
| Genes, Reporter | 3 | 2003 | 798 | 0.030 |
Why?
|
| Azoxymethane | 1 | 2013 | 43 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1999 | 2232 | 0.030 |
Why?
|
| Dextran Sulfate | 1 | 2013 | 72 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 218 | 0.030 |
Why?
|
| Clone Cells | 2 | 2010 | 555 | 0.030 |
Why?
|
| Melanoma | 1 | 2010 | 5317 | 0.030 |
Why?
|
| Protein Conformation | 2 | 1995 | 1258 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2013 | 120 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 1994 | 365 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 265 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1995 | 614 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 2796 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 1053 | 0.030 |
Why?
|
| Sex Characteristics | 2 | 2008 | 417 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3821 | 0.030 |
Why?
|
| Financing, Government | 1 | 2012 | 40 | 0.030 |
Why?
|
| Age Factors | 2 | 2015 | 5377 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2012 | 74 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2014 | 241 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2013 | 392 | 0.030 |
Why?
|
| Base Composition | 1 | 1992 | 92 | 0.030 |
Why?
|
| Cell Communication | 1 | 1995 | 509 | 0.030 |
Why?
|
| Pyridines | 1 | 1999 | 1244 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2013 | 261 | 0.030 |
Why?
|
| Muscle Cells | 1 | 2012 | 38 | 0.030 |
Why?
|
| Wnt1 Protein | 1 | 2012 | 103 | 0.030 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2012 | 122 | 0.030 |
Why?
|
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2011 | 13 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2014 | 251 | 0.030 |
Why?
|
| Guanidine | 1 | 1991 | 12 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2003 | 323 | 0.030 |
Why?
|
| Exostoses, Multiple Hereditary | 1 | 1991 | 26 | 0.030 |
Why?
|
| Research Support as Topic | 1 | 2012 | 122 | 0.030 |
Why?
|
| Growth Plate | 1 | 1991 | 46 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 446 | 0.030 |
Why?
|
| Chick Embryo | 3 | 1987 | 242 | 0.030 |
Why?
|
| Guanidines | 1 | 1991 | 60 | 0.030 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2011 | 60 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 280 | 0.030 |
Why?
|
| Melanoma, Experimental | 1 | 2014 | 368 | 0.030 |
Why?
|
| Cesium Radioisotopes | 1 | 2011 | 39 | 0.030 |
Why?
|
| Mutagenicity Tests | 1 | 2011 | 69 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2011 | 89 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 3719 | 0.020 |
Why?
|
| Cell Line, Transformed | 2 | 2003 | 394 | 0.020 |
Why?
|
| Pigmentation | 1 | 2010 | 47 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2218 | 0.020 |
Why?
|
| Plicamycin | 1 | 2010 | 30 | 0.020 |
Why?
|
| Radiography | 1 | 2015 | 1904 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 130 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 483 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1998 | 1616 | 0.020 |
Why?
|
| Dromaiidae | 1 | 2009 | 3 | 0.020 |
Why?
|
| Zinostatin | 1 | 2009 | 4 | 0.020 |
Why?
|
| E2F5 Transcription Factor | 1 | 2009 | 8 | 0.020 |
Why?
|
| Blastocyst | 1 | 2010 | 124 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2010 | 148 | 0.020 |
Why?
|
| E2F2 Transcription Factor | 1 | 2009 | 27 | 0.020 |
Why?
|
| Rad51 Recombinase | 1 | 2010 | 126 | 0.020 |
Why?
|
| E2F4 Transcription Factor | 1 | 2009 | 30 | 0.020 |
Why?
|
| Colitis | 1 | 2013 | 340 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2011 | 4844 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 2927 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 460 | 0.020 |
Why?
|
| Colon | 1 | 2013 | 670 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2010 | 429 | 0.020 |
Why?
|
| Arginine | 2 | 2007 | 500 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 1688 | 0.020 |
Why?
|
| Learning | 1 | 2012 | 403 | 0.020 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2009 | 174 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 21445 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1082 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 2979 | 0.020 |
Why?
|
| Genes, Viral | 1 | 1988 | 202 | 0.020 |
Why?
|
| Etoposide | 1 | 2009 | 870 | 0.020 |
Why?
|
| Antigens, Viral, Tumor | 1 | 1987 | 47 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 1987 | 61 | 0.020 |
Why?
|
| Adolescent | 4 | 2011 | 31252 | 0.020 |
Why?
|
| Incidence | 2 | 2010 | 5673 | 0.020 |
Why?
|
| Embryo Loss | 1 | 2007 | 42 | 0.020 |
Why?
|
| Centrosome | 1 | 2007 | 95 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1986 | 542 | 0.020 |
Why?
|
| Receptors, Serotonin | 1 | 1986 | 46 | 0.020 |
Why?
|
| Molecular Weight | 3 | 2001 | 629 | 0.020 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1987 | 133 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2010 | 825 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 1293 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1987 | 259 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2007 | 110 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 1869 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2006 | 4988 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2007 | 369 | 0.020 |
Why?
|
| Adenoma | 1 | 2011 | 716 | 0.020 |
Why?
|
| Acetylation | 1 | 2007 | 508 | 0.020 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2005 | 82 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 689 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.020 |
Why?
|
| Glycine | 1 | 2007 | 289 | 0.020 |
Why?
|
| Xenobiotics | 1 | 2005 | 44 | 0.020 |
Why?
|
| Brain | 2 | 1996 | 4113 | 0.020 |
Why?
|
| Epithelium | 2 | 1998 | 720 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 852 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 810 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2005 | 198 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2012 | 32848 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2004 | 189 | 0.020 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2005 | 126 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 170 | 0.020 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2004 | 87 | 0.020 |
Why?
|
| Biological Evolution | 1 | 1985 | 278 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1999 | 1618 | 0.010 |
Why?
|
| Genes, Suppressor | 1 | 2003 | 25 | 0.010 |
Why?
|
| Transcription Factor Brn-3 | 1 | 2002 | 11 | 0.010 |
Why?
|
| Transcription Factor Brn-3A | 1 | 2002 | 9 | 0.010 |
Why?
|
| NIH 3T3 Cells | 1 | 2003 | 260 | 0.010 |
Why?
|
| Lung | 1 | 2014 | 3151 | 0.010 |
Why?
|
| Cytokines | 1 | 2012 | 2809 | 0.010 |
Why?
|
| Doxycycline | 1 | 2003 | 178 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 2003 | 92 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4298 | 0.010 |
Why?
|
| Philadelphia Chromosome | 1 | 2006 | 793 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 2003 | 173 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 827 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2003 | 475 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2003 | 359 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 332 | 0.010 |
Why?
|
| Infant | 2 | 2011 | 13310 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2002 | 150 | 0.010 |
Why?
|
| Piperazines | 1 | 2010 | 2101 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2001 | 157 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2004 | 6869 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2011 | 16273 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2002 | 471 | 0.010 |
Why?
|
| Galactose | 1 | 2001 | 87 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 769 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2001 | 287 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2001 | 293 | 0.010 |
Why?
|
| p21-Activated Kinases | 1 | 2001 | 122 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2001 | 549 | 0.010 |
Why?
|
| Lac Operon | 1 | 1999 | 122 | 0.010 |
Why?
|
| SOX9 Transcription Factor | 1 | 2001 | 170 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2008 | 2086 | 0.010 |
Why?
|
| Caspases | 1 | 2002 | 661 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 2001 | 469 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 869 | 0.010 |
Why?
|
| Centromere Protein B | 1 | 1998 | 5 | 0.010 |
Why?
|
| Drug Design | 1 | 2001 | 375 | 0.010 |
Why?
|
| DNA, Satellite | 1 | 1998 | 36 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 37905 | 0.010 |
Why?
|
| Cations | 1 | 1998 | 62 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1998 | 125 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2000 | 1062 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1999 | 334 | 0.010 |
Why?
|
| Bronchial Neoplasms | 1 | 1998 | 79 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2011 | 8223 | 0.010 |
Why?
|
| DNA, Fungal | 1 | 1998 | 127 | 0.010 |
Why?
|
| X-Rays | 1 | 1998 | 146 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1998 | 181 | 0.010 |
Why?
|
| Lactoglobulins | 1 | 1997 | 2 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1999 | 694 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2003 | 1299 | 0.010 |
Why?
|
| Tretinoin | 1 | 1999 | 623 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1997 | 162 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1997 | 385 | 0.010 |
Why?
|
| Liposomes | 1 | 1998 | 684 | 0.010 |
Why?
|
| Biological Transport | 1 | 1997 | 597 | 0.010 |
Why?
|
| Child | 2 | 2011 | 29154 | 0.010 |
Why?
|
| Bryostatins | 1 | 1995 | 12 | 0.010 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 1995 | 13 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1995 | 110 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1997 | 292 | 0.010 |
Why?
|
| Macrolides | 1 | 1995 | 62 | 0.010 |
Why?
|
| Testis | 1 | 1999 | 717 | 0.010 |
Why?
|
| Cattle | 1 | 1997 | 783 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 1997 | 663 | 0.010 |
Why?
|
| Lactones | 1 | 1995 | 94 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1998 | 1519 | 0.010 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 1994 | 95 | 0.010 |
Why?
|
| Liver Regeneration | 1 | 1995 | 134 | 0.010 |
Why?
|
| Glucose | 1 | 2001 | 1248 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 7702 | 0.010 |
Why?
|
| Carcinoma | 1 | 2004 | 2578 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1995 | 258 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 1998 | 1058 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 2992 | 0.010 |
Why?
|
| Extremities | 1 | 1991 | 303 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1997 | 1390 | 0.010 |
Why?
|
| Hepatectomy | 1 | 1995 | 1011 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1995 | 4938 | 0.000 |
Why?
|
| Radioligand Assay | 1 | 1986 | 54 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1985 | 117 | 0.000 |
Why?
|
| Trypsin | 1 | 1985 | 140 | 0.000 |
Why?
|
| Procollagen | 1 | 1985 | 31 | 0.000 |
Why?
|
| Tumor Virus Infections | 1 | 1986 | 224 | 0.000 |
Why?
|
| Antigens, Viral | 1 | 1986 | 471 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 29902 | 0.000 |
Why?
|
| Amino Acids | 1 | 1985 | 728 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1980 | 121 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1985 | 1271 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1980 | 600 | 0.000 |
Why?
|